APM
VERV

Avidity Partners Management’s Verve Therapeutics VERV Stock Holding History

Avidity Partners Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-285,334
Closed -$3.78M – 89
2023
Q3 		$3.78M Sell
285,334
-593,266
-68% -$9.55M 0.15% 76
2023
Q2 		$16.5M Sell
878,600
-473,100
-35% -$7.88M 0.58% 59
2023
Q1 		$19.5M Sell
1,351,700
-213,300
-14% -$4.18M 0.65% 50
2022
Q4 		$30.3M Buy
1,565,000
+522,294
+50% +$13.8M 0.66% 43
2022
Q3 		$35.8M Buy
+1,042,706
New +$33.3M 0.73% 44

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Avidity Partners Management's VERV Position: Q4 2023 in Review

Avidity Partners Management sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 285,334 shares — an estimated $3.78M sold.

Avidity Partners Management first reported a position in VERV in Q3 2022 and held it in 5 quarters. The position peaked at $35.8M in Q3 2022. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Avidity Partners Management reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Avidity Partners Management sold 285,334 Verve Therapeutics shares in Q4 2023, an estimated $3.78M.
  • Avidity Partners Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 5 quarters.
  • Avidity Partners Management's Verve Therapeutics position peaked at $35.8M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.